The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is characterised by many comorbidities related to aberrant mucosa and chronic inflammation in the respiratory and digestive systems. The intestinal mucosa serves as the primary interface between the gut microbiota and endocrine, neural and immune systems. There is emerging evidence that aberrant intestinal mucosa in CF may associate with an altered gut microbiota. Compared to healthy subjects, the overall bacterial abundance and species richness seems to be reduced in CF, accompanied by a trend in suppression of Firmicutes and Bacteroidetes spp. and an augmentation of potentially pathogenic species. There is also some concordance of gut and respiratory microbiotas in CF infants over time. The clinical significance of these observations awaits investigation. The gut microbiota have some potential in CF management by affecting inflammatory and immune responses, and influencing aberrant mucosa. As an important modifiable factor, diet therapies such as probiotics and prebiotics have shown initial promise in improving CF related conditions associated with chronic inflammation. More studies are needed to confirm this, as well as the efficacy of other dietary strategies such as modulating dietary fat and indigestible carbohydrate. Similarly, dietary modification of gut microbiota to optimise nutritional status in CF may be feasible, although more CF-specific studies are warranted.

Original languageEnglish
Pages (from-to)571-580
Number of pages10
JournalClinical Nutrition
Volume33
Issue number4
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Fingerprint

Cystic Fibrosis
Diet Therapy
Therapeutics
Intestinal Mucosa
Mucous Membrane
Bacteroidetes
Inflammation
Prebiotics
Digestive System
Endocrine System
Gastrointestinal Microbiome
Dietary Fats
Probiotics
Nutritional Status
Respiratory System
Comorbidity
Immune System
Healthy Volunteers
Carbohydrates

Cite this

@article{fb48ed6f8c20407f93a940bfad118c23,
title = "The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies",
abstract = "Cystic fibrosis (CF) is characterised by many comorbidities related to aberrant mucosa and chronic inflammation in the respiratory and digestive systems. The intestinal mucosa serves as the primary interface between the gut microbiota and endocrine, neural and immune systems. There is emerging evidence that aberrant intestinal mucosa in CF may associate with an altered gut microbiota. Compared to healthy subjects, the overall bacterial abundance and species richness seems to be reduced in CF, accompanied by a trend in suppression of Firmicutes and Bacteroidetes spp. and an augmentation of potentially pathogenic species. There is also some concordance of gut and respiratory microbiotas in CF infants over time. The clinical significance of these observations awaits investigation. The gut microbiota have some potential in CF management by affecting inflammatory and immune responses, and influencing aberrant mucosa. As an important modifiable factor, diet therapies such as probiotics and prebiotics have shown initial promise in improving CF related conditions associated with chronic inflammation. More studies are needed to confirm this, as well as the efficacy of other dietary strategies such as modulating dietary fat and indigestible carbohydrate. Similarly, dietary modification of gut microbiota to optimise nutritional status in CF may be feasible, although more CF-specific studies are warranted.",
keywords = "Chronic inflammation, Cystic fibrosis, Diet therapy, Gut microbiota",
author = "Li Li and Shawn Somerset",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clnu.2014.04.004",
language = "English",
volume = "33",
pages = "571--580",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "4",

}

The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies. / Li, Li; Somerset, Shawn.

In: Clinical Nutrition, Vol. 33, No. 4, 01.01.2014, p. 571-580.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies

AU - Li, Li

AU - Somerset, Shawn

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cystic fibrosis (CF) is characterised by many comorbidities related to aberrant mucosa and chronic inflammation in the respiratory and digestive systems. The intestinal mucosa serves as the primary interface between the gut microbiota and endocrine, neural and immune systems. There is emerging evidence that aberrant intestinal mucosa in CF may associate with an altered gut microbiota. Compared to healthy subjects, the overall bacterial abundance and species richness seems to be reduced in CF, accompanied by a trend in suppression of Firmicutes and Bacteroidetes spp. and an augmentation of potentially pathogenic species. There is also some concordance of gut and respiratory microbiotas in CF infants over time. The clinical significance of these observations awaits investigation. The gut microbiota have some potential in CF management by affecting inflammatory and immune responses, and influencing aberrant mucosa. As an important modifiable factor, diet therapies such as probiotics and prebiotics have shown initial promise in improving CF related conditions associated with chronic inflammation. More studies are needed to confirm this, as well as the efficacy of other dietary strategies such as modulating dietary fat and indigestible carbohydrate. Similarly, dietary modification of gut microbiota to optimise nutritional status in CF may be feasible, although more CF-specific studies are warranted.

AB - Cystic fibrosis (CF) is characterised by many comorbidities related to aberrant mucosa and chronic inflammation in the respiratory and digestive systems. The intestinal mucosa serves as the primary interface between the gut microbiota and endocrine, neural and immune systems. There is emerging evidence that aberrant intestinal mucosa in CF may associate with an altered gut microbiota. Compared to healthy subjects, the overall bacterial abundance and species richness seems to be reduced in CF, accompanied by a trend in suppression of Firmicutes and Bacteroidetes spp. and an augmentation of potentially pathogenic species. There is also some concordance of gut and respiratory microbiotas in CF infants over time. The clinical significance of these observations awaits investigation. The gut microbiota have some potential in CF management by affecting inflammatory and immune responses, and influencing aberrant mucosa. As an important modifiable factor, diet therapies such as probiotics and prebiotics have shown initial promise in improving CF related conditions associated with chronic inflammation. More studies are needed to confirm this, as well as the efficacy of other dietary strategies such as modulating dietary fat and indigestible carbohydrate. Similarly, dietary modification of gut microbiota to optimise nutritional status in CF may be feasible, although more CF-specific studies are warranted.

KW - Chronic inflammation

KW - Cystic fibrosis

KW - Diet therapy

KW - Gut microbiota

UR - http://www.scopus.com/inward/record.url?scp=84902366435&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2014.04.004

DO - 10.1016/j.clnu.2014.04.004

M3 - Review article

VL - 33

SP - 571

EP - 580

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 4

ER -